



Date: April 18, 2008

To: NCCTG Primary Clinical Research Associates

From: Sara Braun  
Protocol Development Coordinator

Subject: N0275, Phase II Trial Evaluating Resection followed by Adjuvant Radiation Therapy (RT) for Patients with Desmoplastic Melanoma

Attached are updated forms:

Eligibility Checklist:

Editorial changes only which include:

- “Randomization Center” has changed to “Registration Office”
- Patient study ID number had the following instructional information added: *(provided at time of Registration)*
- Demographics were updated to current NCI verbiage

Pathology Reporting Form:

Editorial changes only which include:

- Updated verbiage (pages 1 and 2) from “II. Completed by central pathology reviewer” to “II. Completed by the NCCTG Central Pathology reviewer”
- Section III – “Reviewer” now reads “NCCTG Pathology Review” and “Committee Chairman” now reads “Committee Chairperson”

Section 111 – Results verbiage changes:

- “1. Agree with diagnosis” now reads “1. Agree with original local diagnosis”
- “2. Minor disagreement” now reads “2. Minor disagreement with original local diagnosis”
- “3. Substantial disagreement” now reads “3. Substantial disagreement with original local diagnosis”

If you have any questions, please contact me at 507/538-8226.

Thank you.

SB/dg  
Enclosure